Danaher CORP /DE/ 8-K filings

Danaher Corporation announced the appointment of Julie Sawyer Montgomery as its new President and Chief Executive Officer, effective October 1, 2026, succeeding Rainer Blair.

Danaher Corporation announced the issuance and sale of approximately CHF 1.90 billion in senior notes across seven series, maturing between 2031 and 2056, to fund general corporate purposes.

Danaher Corporation's annual shareholder meeting on May 5, 2026, saw overwhelming approval for the Amended and Restated Omnibus Incentive Plan and the election of directors.

Danaher Corporation enters into a new $5.0 billion 364-day revolving credit facility to provide liquidity support for its commercial paper program and general corporate needs.

Danaher Corporation announced a definitive agreement to acquire Masimo Corporation for $180 per share in cash, totaling approximately $9.9 billion.

Danaher Corporation announced the retirement of Dr. Jessica L. Mega from its Board of Directors, effective February 5, 2026, citing other professional commitments.

Danaher Corporation anticipates fourth quarter 2025 financial results to be slightly ahead of expectations, driven by strong Bioprocessing, Life Sciences, and Diagnostics performance.

Danaher Corporation announced that director John T. Schwieters will retire from the Board at the 2026 annual meeting of shareholders, reducing the board size to twelve members.

Danaher Corporation reported strong third-quarter 2025 results, surpassing revenue, earnings, and cash flow expectations, fueled by bioprocessing and Cepheid's respiratory revenue.

Danaher Corporation's Board of Directors approved a new 35 million share repurchase program and amended its By-laws to revise shareholder proposal and director nomination procedures.

Danaher Corporation announced that Brian W. Ellis will step down as General Counsel on August 25, 2025, continuing as Senior Vice President until his retirement on February 28, 2026.

Danaher Corporation announced a planned Chief Financial Officer transition, with Matthew Gugino succeeding Matthew McGrew effective February 28, 2026, as Mr. McGrew transitions towards retirement.

Danaher Corporation reported second quarter 2025 financial results that exceeded expectations, driven by strong Bioprocessing growth and disciplined cost management, leading to an increase in full-year adjusted diluted net earnings per common share guidance.

Danaher Corporation successfully held its annual shareholder meeting on May 6, 2025, electing all director nominees and approving the ratification of the independent accounting firm and executive compensation.

Danaher Corporation announced its first quarter 2025 results, exceeding expectations with adjusted diluted net earnings per share of $1.88 and flat core revenue year-over-year.

Danaher Corporation appoints Charles W. Lamanna to its Board of Directors and amends its 2007 Omnibus Incentive Plan to enhance benefits upon death or disability.

Danaher Corporation announces its Q4 and full year 2024 financial results, highlighting revenue growth and strong cash flow, while projecting continued growth into 2025.

Danaher Corporation expects its fourth-quarter 2024 core revenue to be essentially flat year-over-year, surpassing previous guidance of a low-single-digit decline.

Danaher Corporation reports the retirement of board member Pardis C. Sabeti, effective December 10, 2024, due to time commitments.

Danaher Corporation announced better-than-expected third quarter results, with revenue growth driven by its bioprocessing business and market share gains in molecular testing.

Danaher Corporation announced its second quarter 2024 results, exceeding expectations with strong performance in bioprocessing and molecular testing, despite a slight revenue decrease.

Danaher Corporation's Executive Vice President, Joakim Weidemanis, will step down from his position on July 1, 2024, with a transition agreement in place until September 30, 2024.

Danaher Corporation held its annual shareholder meeting on May 7, 2024, where directors were elected, the company's auditor was ratified, executive compensation was approved, and two shareholder proposals were rejected.

Danaher Corporation announced its first quarter 2024 results, showing a decrease in revenue but better-than-expected earnings and cash flow.

Walter G. Lohr, Jr. will retire from Danaher's Board of Directors at the annual shareholder meeting on May 7, 2024, after deciding not to stand for reelection.

Danaher Corporation announced a decrease in revenue for both the fourth quarter and full year 2023, while also exceeding margin and cash flow expectations.